• Clearmind Medicine completed Part A treatment in its FDA-regulated Phase I/II trial of CMND-100 for Alcohol Use Disorder.
• Results have not been presented; the dataset is under review.
• All 24 participants across four cohorts finished dosing under the study protocol.
• Next-stage initiation is planned if the review remains favorable, marking a potential advance in its AUD development program.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606220807PRIMZONEFULLFEED9750324) on June 22, 2026, and is solely responsible for the information contained therein.